drugset / Trial / NCT07435779
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
NaSingle-groupOpen-labelTreatment
Summary
A Single-Center, Open-Label, Single-Arm Exploratory Clinical Study on the Use of Autologous CAR-T Cell Therapy Injection for the Treatment of Refractory and Relapsing Ulcerative Colitis: A Preliminary Exploration of 12-Week Clinical Remission with Autologous CAR-T Cell Injection in Refractory and Relapsing Ulcerative Colitis.
Timeline
- Start
- 2026-02-04
- Primary completion
- 2027-02-04
- Completion
- 2028-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD19 CAR-T | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD19×BCMA | Cell therapy | 1e+06 cells/kg | Intravenous |
Indications
No indication recorded.